Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New eye drop combo shows promise for reading without glasses

NCT ID NCT04675151

Symptom relief Sponsor: Ocuphire Pharma, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a combination of two eye drops (Nyxol and pilocarpine) can help people with presbyopia—age-related difficulty seeing up close—read better without glasses. About 150 adults aged 40 to 64 took part. The main goal was to see how many people could read 15 or more extra letters on an eye chart one hour after using the drops, compared to their starting vision.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

150 people

The number who actually took part.

Started

Feb 2021

Finished

Jun 2021

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 64 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Males or females ≥ 40 and ≤ 64years of age. 2. BCDVA of 0.0 LogMAR(20/20 Snellen equivalent) or better in each eye under photopic conditions. 3. DCNVA of 0.4 LogMAR (20/50 Snellen equivalent) or worse under photopic conditions in each eye and binocularly. 4. Subjects who depend on reading glasses or bifocals in which their binocular best-corrected near VA is 0.1 LogMAR (20/25 Snellen equivalent) or better. Exclusion Criteria: Ophthalmic (in either eye): 1. Use of any topical prescription or OTC ophthalmic medications of any kind within 7 days of Screening until study completion. 2. Use of any over-the-counter (OTC) artificial tears (preserved or unpreserved) at least once per day within 7 days of Screening until study completion. 3. Current use of any topical ophthalmic therapy for dry eye. 4. Tear break-up time of \< 5 seconds or corneal fluorescein staining. 5. Clinically significant ocular disease that might interfere with the study as deemed by the Investigator. 6. Recent or current evidence of ocular infection or inflammation in either eye. 7. Any history of herpes simplex or herpes zoster keratitis. 8. History of diabetic retinopathy or diabetic macular edema. 9. Known allergy, hypersensitivity, or contraindication to any component of the phentolamine, pilocarpine, or vehicle formulations. 10. History of cauterization of the punctum or punctal plug (silicone or collagen) insertion or removal. 11. Ocular trauma, ocular surgery, ocular laser treatment within the 6 months prior to Screening. Any subject with multifocal intraocular lenses are excluded. 12. History of any traumatic (surgical or nonsurgical) or non traumatic condition affecting the pupil or iris. 13. Unwilling or unable to discontinue use of contact lenses. 14. Conjunctival hyperemia ≥ grade 2 on the CCLRU 4-point scale. Systemic: 15. Known hypersensitivity or contraindication to alpha- and/or beta adrenoceptor antagonists. 16. Known hypersensitivity or contraindication to any systemic cholinergic parasympathomimetic agents. 17. Clinically significant systemic disease that might interfere with the study as deemed by the Investigator. 18. Participation in any investigational study within 30 days prior to Screening. 19. Females of childbearing potential who are pregnant, nursing, planning a pregnancy, or not using a medically acceptable form of birth control. 20. Resting HR outside the specified range of 50 to 110 beats per minute. 21. Hypertension with resting diastolic BP \> 105 mmHg or systolic BP \> 160 mmHg.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Presbyopia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

presbyopia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Presbyopia

Contacts and locations

Locations

  • Clinical Site 1

    Memphis, Tennessee, 38119, United States

  • Clinical Site 10

    Roswell, Georgia, 30041, United States

  • Clinical Site 11

    Maitland, Florida, 32751, United States

  • Clinical Site 12

    Laguna Hills, California, 92653, United States

  • Clinical Site 13

    Crystal River, Florida, 34461, United States

  • Clinical Site 14

    Fargo, North Dakota, 58103, United States

  • Clinical Site 15

    Powell, Ohio, 43065, United States

  • Clinical Site 16

    Poughkeepsie, New York, 12603, United States

  • Clinical Site 18

    St Louis, Missouri, 63101, United States

  • Clinical Site 2

    Athens, Ohio, 45701, United States

  • Clinical Site 3

    Pittsburg, Kansas, 66762, United States

  • Clinical Site 4

    Warwick, Rhode Island, 02888, United States

  • Clinical Site 5

    Longwood, Florida, 32779, United States

  • Clinical Site 6

    Newport Beach, California, 92663, United States

  • Clinical Site 7

    Cleveland, Ohio, 44115, United States

  • Clinical Site 8

    Sarasota, Florida, 34239, United States

  • Clinical Site 9

    Cincinnati, Ohio, 45242, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.